Seminars in Oncology
Volume 33 , Pages S1-S7 , October 2006

Mechanisms of Action of Bevacizumab as a Component of Therapy for Metastatic Colorectal Cancer

  • Lee M. Ellis

      Affiliations

    • Dr Ellis is a consultant to ImClone Systems Inc, Genentech, Inc, Novartis AG, and Amgen Inc. He has received research support from ImClone Systems Inc and Amgen, and is on the speakers bureau at Genentech, Inc.
    • Corresponding Author InformationAddress reprint requests to Lee M. Ellis, MD, University of Texas M. D. Anderson Cancer Center, Box 301402, Houston, TX 77230, USA

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This work was supported in part by the Lustgarten Foundation for Pancreatic Cancer Research, National Institutes of Health grant no. CA112390, and the Lockton Fund for Pancreatic Cancer Research. The author thanks Genentech, Inc, for providing financial support for the editorial services of ApotheCom Associates.

PII: S0093-7754(06)00313-7

doi: 10.1053/j.seminoncol.2006.08.002

Seminars in Oncology
Volume 33 , Pages S1-S7 , October 2006

Article Tools

* Image Usage & Resolution